Contraline, a University of Virginia Licensing & Ventures Group venture, has made big news.

The company released data that suggests that it is possible for its male contraceptive, known as "ADAM," to achieve similar levels of efficacy as long-acting female contraceptives like IUDs.

“We are thrilled to share these positive results which we believe take us one step closer to transforming the contraceptive landscape,” Contraline CEO and cofounder Kevin Eisenfrats said.

Click here to read the full story that appeared in the New York Post.